摘要
目的观察充血性心力衰竭(CHF)患者sFas/APO-1与心肌重塑的变化及培哚普利对其的影响,探讨培哚普利改善CHF患者心功能的可能机制。方法选择CHF患者56例,随机分组,A组(26例)为常规治疗组,B组(30例)在常规治疗基础上加用培哚普利(4mg,Qd)治疗共3个月,分别于0、3个月末采用酶联免疫吸附双抗体夹心法(ELISA法)测定血清sFas/APO-1水平,采用超声心动图诊断方法测定左心室收缩末径(LVESD)、左心室舒张末径(LVEDD)、每搏输出量(SV)和左心室射血分数(LVEF)等,另设健康对照组20例。结果心力衰竭患者血清sFas/APO-1水平明显高于健康对照组,培哚普利组治疗3个月后,较常规治疗组血清sFas/APO-1水平明显下降,LVESD、LVEDD明显减低,SV与LVEF明显升高,差异均有统计学意义;sFas/APO-1水平与LVEF呈负相关。结论培哚普利可明显改善CHF患者心肌重塑与心功能,其作用机制可能与降低血清sFas/APO-1水平有关。
Objective To observe the variations of sFas/APO- 1 and myocardial remodeling in patients with congestive heart failure （CHF） and the therapeutic effect of perindopil, and to investigate the possible mechanism of perindopil for improving patients with CHF. Methods Fifty - six patients with CHF were randomly divided into two groups. Group A （n = 26） were given conventional therapy, wherase group B（n= 30） received additional 4mg perindopil daily on the basis of conventional therapy for three months. Another 20 healthy persons were recruited as the control group. The levels of serum sFas/APO- 1, left ventrioular east systolic diameter（LVESD）, left ventrioular east diastolic diameter （LVEDD）, stroke volume （SV） and left ventricular ejection fraction（LVEF） were monitored and compared before and 3 months after the treatment. Results Pa- tients with CHF had a higher level of serum sFas/APO- 1 than that of the control group. After 3 months therapy with additional perindopil, levels of serum sFas/APO- 1, LVESD and LVEDD in group B were significantly decreased than those of the group A with only conventional therapy, while SV and LVEF were significantly increased in group B. Serum sFas/APO - 1 correlated positively with LVEF. Conclusions Perindopil improves patients with CHF in myocardial remodeling and heart function, and its possible mechanism may be related to the reduced level of serum sFas/APO-1.
出处
《实用预防医学》
CAS
2007年第3期630-632,共3页
Practical Preventive Medicine
基金
湖南省卫生厅资助课题(2001-Y49)
